Worsening of Cardiomyopathy Using Deflazacort in an Animal Model Rescued by Gene Therapy
Author Information
Author(s): Ida Luisa Rotundo, Stefania Faraso, Elvira De Leonibus, Gerardo Nigro, Carmen Vitiello, Alessio Lancioni, Daniele Di Napoli, Sigismondo Castaldo, Vincenzo Russo, Fabio Russo, Giulio Piluso, Alberto Auricchio, Vincenzo Nigro
Primary Institution: Telethon Institute of Genetics and Medicine, Napoli, Italy
Hypothesis
What are the combined effects of steroid treatment and gene therapy on cardiac function?
Conclusion
Gene therapy improves cardiac function in hamsters, but deflazacort treatment may worsen the condition.
Supporting Evidence
- Gene therapy was able to preserve the ejection fraction in treated hamsters.
- Deflazacort treatment led to a decline in ejection fraction when combined with gene therapy.
- Behavioral functions improved in hamsters treated with deflazacort despite weight loss.
Takeaway
This study shows that while gene therapy can help heart problems in hamsters, using steroids like deflazacort might make things worse.
Methodology
Hamsters were treated with gene therapy and deflazacort, and their cardiac function was assessed through echocardiography.
Potential Biases
Potential bias in the interpretation of the effects of deflazacort on cardiac function.
Limitations
The study is limited to an animal model, and results may not directly translate to humans.
Participant Demographics
Male BIO14.6 Syrian hamsters were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website